Summary: This ADC product is comprised of an anti-CEACAM5 monoclonal antibody (clone huMAb2-3) conjugated via a SMCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. http://www.creative-biolabs.com/adc/target-ceacam5-21.htm